Hillhouse Capital Leads Hundreds of Millions RMB Strategic Financing in Shanwaishan, a Leading Blood Purification Company

VCBeat (WeChat ID: vcbeat) has learned that Chongqing Shanwaishan Science&Technology Co.,Ltd. recently announced the completion of a strategic financing round amounting to hundreds of millions of yuan. The round was led by Hillhouse Venture Capital, with participation from Xiangjiang Industry, Xiangjiang Liyuan Jianling, and other investors.

Chongqing Shanwaishan Science&Technology Co.,Ltd. (hereinafter referred to as "SWS MEDICAL") was established in 2001. With over two decades of dedication to the field of blood purification, the company operates across the entire industry chain, integrating blood purification equipment, consumables, intelligent management systems, and a chain of hemodialysis centers. As a leading enterprise in China's blood purification industry, SWS MEDICAL is also a key drafter of industry standards.

SWS MEDICAL possesses national-level technological innovation platforms, including a National Enterprise Technology Center, a National Engineering Research Center, and a National Postdoctoral Research Workstation. The company has mastered core key technologies for high-end blood purification equipment, earning it the Second Prize of the National Science and Technology Progress Award.

As a leading enterprise in the hemodialysis industry, SWS MEDICAL drafted and formulated two national standards and five industrial standards in China’s blood purification field, and is recognized as a National Innovative Enterprise and a National Technological Innovation Demonstration Enterprise. The company has filed 8 international patents and 181 national patents (including 79 invention patents), with 122 patents granted.

SWS MEDICAL has aligned its blood purification technologies and standards with advanced global levels, obtained CE certification, and is on the verge of completing FDA certification. Currently, the company’s products are sold to Europe, Southeast Asia, South America, and other regions, have been adopted by more than 2,000 hospitals domestically and internationally, and have an installed base of over 10,000 hemodialysis machines.

In recent years, leveraging superior product quality and technological advantages, SWS MEDICAL has broken the import monopoly and captured a significant share of the domestic market for hemodialysis equipment. To date, SWS MEDICAL’s hemodialysis machines (SWS-4000, SWS-4000A, SWS-6000, SWS-6000A, SWS-6000B) and hemoperfusion machine (SWS-2000A) have been included in the Catalogue of Excellent Domestic Medical Equipment Products with high scores, owing to their outstanding technical specifications and corporate qualifications, thereby dominating the blood purification industry rankings. On September 19, 2019, at the 2019 Annual Academic Conference of the Chinese Society of Nephrology under the Chinese Medical Association in Hangzhou, SWS MEDICAL prominently launched the SWS-5000 series of continuous blood purification equipment (CRRT + Artificial Liver). As one of the most powerful devices with the broadest range of indications among similar products globally, it has received widespread acclaim and strong market demand, marking a new milestone for domestic blood purification equipment.

Following the outbreak of the COVID-19 pandemic, SWS MEDICAL was included in the list of key enterprises guaranteed for epidemic prevention and control supplies by the National Development and Reform Commission (NDRC), the National Health Commission (NHC), and the Ministry of Industry and Information Technology (MIIT). The company’s independently developed SWS-5000 series Continuous Renal Replacement Therapy (CRRT) and Artificial Liver Support System devices, renowned for their superior quality, advanced technology, and robust blood purification capabilities, were utilized in the blood purification treatment of severe COVID-19 patients (combining plasma therapy and artificial liver therapy). These devices played a crucial role in saving critically ill patients with COVID-19 and received commendation and awards from the State Council’s Leading Group for Epidemic Prevention and Control.

The SWS-5000 series of continuous blood purification devices (CRRT + artificial liver) has been widely used in medical institutions in Italy, Azerbaijan, South Africa, Greece, and many other countries and regions, making significant contributions to international epidemic prevention efforts.

Since its establishment in 2001, SWS MEDICAL has continuously strengthened independent innovation. The company has now built an intelligent manufacturing facility for blood purification equipment and consumables, achieving quality traceability and full lifecycle management across all stages, including R&D, procurement, production, inspection, clinical use, and operation and maintenance.

In addition, the Industrial Internet Identity Resolution Secondary Node Platform for the medical device industry, constructed by SWS MEDICAL, has been officially connected to the National Top-Level (Chongqing) Node, becoming the first secondary node in the medical device industry in western China.

The head of Hillhouse Capital’s healthcare and medical devices investment division stated, “In recent years, the number of hemodialysis patients in China has been on the rise. Hemodialysis equipment plays a significant role in alleviating patient symptoms and extending survival rates, while also helping to reduce the burden on the national medical insurance system. SWS MEDICAL has consistently adhered to an innovation-driven strategy, enhancing its core competitiveness through technological advancements and service upgrades. The company has broken the monopoly held by imported products and established strong brand recognition and reputation for domestically produced blood purification systems within the industry. We will continue to support the company’s R&D and innovation efforts, promoting the continuous development of domestically manufactured medical devices to benefit more patients.”